Another Rituximab Debuts In India But No Price Contest?
This article was originally published in PharmAsia News
Executive Summary
The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.
You may also be interested in...
Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology
Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”
'Affordable' Russian Rituximab Biosimilar On Course In India
Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.
'Affordable' Russian Rituximab Biosimilar On Course In India
Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.